Cardiovascular effects of fingolimod: A review article

Multiple sclerosis (MS) is a chronic auto-immune disease. Most therapeutic strategies for treatment of this disease direct immune modulation and control of inflammatory processes. First-line therapeutic agents showed moderate efficacy and frequent side-effects with moderate efficacy in trials. Their parental administration and limited long-term adherence restrict their efficacy compared with second-line therapies. Fingolimod as a second-line therapeutic agent has been shown to reduce annualized relapse rate, risk of disability progression and inflammatory activity of relapsing MS. Safety and efficacy FTY720: Safety and efficacy issues are the main metrics for judgment of drug efficacy. In this article, we focus on cardiovascular effects of FTY720 treatment. Effect of FTY720 on rate and rhythm, impact of FTY720 on endothelial cells, its atheroprotective effects, its effects on cardiac transplantation outcomes, vascular complications of FTY720, effects of FTY720 on endocrine functions and interaction of FTY720 with cardioactive agents are explained in this review article.

• Publication year

  2014

• Venue

  Iranian journal of neurology

• Publication date

  2014-07-04

• Fields of study

  Medicine

• Identifiers
  PMID 25422729PMCID 4240927
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?

  2013cited by this paper
• Novel drugs targeting sphingolipid metabolism.

  2013cited by this paper
• Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.

  2013cited by this paper
• Factors affecting bone mineral density in multiple sclerosis patients

  2013cited by this paper
• The molecular study of IFNβ pleiotropic roles in MS treatment

  2013cited by this paper
• Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod

  2013influential reference
• Sphingosine 1-phosphate receptor agonists: a patent review (2010 – 2012)

  2013cited by this paper
• Fingolimod attenuates ceramide-induced blood–brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes

  2012cited by this paper
• [Sphingosine 1-phosphate receptors: from biology to physiopathology].

  2012cited by this paper
• Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain

  2012cited by this paper
• The Clinically-tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P1) and Hypertension (S1P3) in Rat

  2012cited by this paper
• Sphingosine 1-Phosphate Receptor Signaling Regulates Proper Embryonic Vascular Patterning*

  2012cited by this paper
• Targeting intracerebral inflammation in multiple sclerosis: is it feasible?

  2012cited by this paper
• Oral FTY720 Administration Induces Immune Tolerance and Inhibits Early Development of Atherosclerosis in Apolipoprotein E-Deficient Mice

  2012cited by this paper
• Fingolimod-associated macular edema

  2012cited by this paper
• FTY720 Protects Cardiac Microvessels of Diabetes: A Critical Role of S1P1/3 in Diabetic Heart Disease

  2012cited by this paper
• [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].

  2012cited by this paper
• Sphingosine-1-Phosphate Receptor 3 Promotes Recruitment of Monocyte/Macrophages in Inflammation and Atherosclerosis

  2011cited by this paper
• Intracellular S1P Generation Is Essential for S1P-Induced Motility of Human Lung Endothelial Cells: Role of Sphingosine Kinase 1 and S1P Lyase

  2011cited by this paper
• Sphingosine 1-phosphate in coagulation and inflammation

  2011cited by this paper
• Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis

  2011cited by this paper
• Pak1 as a Novel Therapeutic Target for Antihypertrophic Treatment in the Heart

  2011cited by this paper
• Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers

  2011cited by this paper
• Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury

  2011cited by this paper
• Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis

  2011cited by this paper
• FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling.

  2010cited by this paper
• Sphingosine 1-Phosphate (S1P) Regulates Vascular Contraction via S1P3 Receptor: Investigation Based on a New S1P3 Receptor Antagonist

  2010cited by this paper
• Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (Fingolimod) in multiple sclerosis

  2010cited by this paper
• Oral fingolimod (gilenya) for multiple sclerosis.

  2010cited by this paper
• FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells

  2010cited by this paper
• Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

  2010cited by this paper
• The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia.

  2009cited by this paper
• Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion.

  2009cited by this paper
• Synthetic Analogs of FTY720 [2-Amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] Differentially Regulate Pulmonary Vascular Permeability in Vivo and in Vitro

  2009cited by this paper
• The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy.

  2009cited by this paper
• The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects.

  2008cited by this paper
• Sphingosine-1-phosphate receptor signalling in the heart.

  2008cited by this paper
• The Sphingosine-1-Phosphate Analogue FTY720 Reduces Atherosclerosis in Apolipoprotein E–Deficient Mice

  2007cited by this paper
• The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients.

  2007cited by this paper
• Effect of FTY720 on apoptosis of smooth muscle cells.

  2007cited by this paper
• Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients.

  2007cited by this paper
• Oral fingolimod (FTY720) for relapsing multiple sclerosis.

  2006cited by this paper
• Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.

  2006cited by this paper
• FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value

  2006cited by this paper
• Preoperative administration of FTY720 prolonged renal allograft survival.

  2005cited by this paper
• Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma

  2005cited by this paper
• FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation

  2005cited by this paper
• Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.

  2004cited by this paper
• The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors

  2004cited by this paper
• FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.

  2004cited by this paper
• FTY720, a new immunosuppressant, as rescue therapy in mouse cardiac transplantation.

  2003cited by this paper
• FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A

  2003cited by this paper
• Phosphorylation and Action of the Immunomodulator FTY720 Inhibits Vascular Endothelial Cell Growth Factor-induced Vascular Permeability*

  2003cited by this paper
• The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2

  2003cited by this paper
• FTY720: A new kid on the block for transplant immunosuppression

  2003cited by this paper
• Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat

  2002cited by this paper
• Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses.

  2002cited by this paper
• FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation.

  2000cited by this paper
• Sphingosine 1‐phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis

  2000cited by this paper
• Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug‐resistant solid tumors by co‐administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin

  2000cited by this paper
• FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation.

  1999cited by this paper
• FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats.

  1996cited by this paper
• Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720.

  1996cited by this paper

• Unmasking the Silent Threat: Prevalence of Cardiovascular Risk Factors in MS Patients in Bucharest, Romania

  2025cites this paper
• Novel Finding of Retinal Aneurysmal Alterations in Patients Undergoing Fingolimod Therapy for Multiple Sclerosis

  2025cites this paper
• Livedo Reticularis in Association with Fingolimod: A Case Report

  2024cites this paper
• A Theranostic Small-Molecule Prodrug Conjugate for Neuroendocrine Prostate Cancer

  2023cites this paper
• The preventive effect of Zingiber officinale essential oil on demyelination of corpus callosum in a cuprizone rat model of multiple sclerosis

  2023cites this paper
• The S1P receptor 1 antagonist Ponesimod reduces TLR4-induced neuroinflammation and increases Aβ clearance in 5XFAD mice

  2023cites this paper
• Recruitment and residence of intestinal T cells - lessons for therapy in IBD.

  2023cites this paper
• The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review

  2022cites this paper
• Updates and advances in multiple sclerosis neurotherapeutics

  2022cites this paper
• Sphingosine 1 phosphate promotes hypertension specific memory T cell trafficking in response to repeated hypertensive challenges

  2022cites this paper
• Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study.

  2022cites this paper
• ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P1 Agonist and Functional Antagonist Potency In Vitro and In Vivo

  2021cites this paper
• Novel compounds with dual S1P receptor agonist and histamine H3 receptor antagonist activities act protective in a mouse model of multiple sclerosis.

  2021cites this paper
• A review of cardiovascular involvements associated with medications used to treat COVID-19 infection

  2021cites this paper
• 2-((2-(4-Iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol (25I-NBOH) and 2-(((2-(4-chloro-2,5-dimethoxyphenyl)ethyl)amino)methyl)phenol (25C-NBOH) induce adverse effects on the cardiovascular system.

  2021cites this paper
• Novel Multiple Sclerosis Agents-Induced Cardiotoxicity

  2021cites this paper
• Protein Kinase C Isozymes and Autophagy during Neurodegenerative Disease Progression

  2020cites this paper
• Fingolimod (FTY720) Preserves High Energy Phosphates and Improves Cardiac Function in Heterotopic Heart Transplantation Model

  2020cites this paper
• Morpholino Analogues of Fingolimod as Novel and Selective S1P1 Ligands with In Vivo Efficacy in a Mouse Model of Experimental Antigen-Induced Encephalomyelitis

  2020cites this paper
• A Double-Edged Sword—Cardiovascular Concerns of Potential Anti-COVID-19 Drugs

  2020cites this paper
• 2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo.

  2019cites this paper
• Cardiotoxic effects of [3-[2-(diethylamino)ethyl]-1H-indol-4-yl] acetate and 3-[2-[ethyl(methyl)amino]ethyl]-1H-indol-4-ol: Short title: QT prolongation by 4-acetoxy-DET and 4-hydroxy-MET.

  2019cites this paper
• Management of relapsing–remitting multiple sclerosis in Qatar: an expert consensus

  2019cites this paper
• Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.

  2019cites this paper
• Cardioprotective Role of Sphingosine 1-Phosphate Receptor Agonist Fingolimod (FTY720) in Global Ischemia-Reperfusion Models

  2017cites this paper
• Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) Attenuates Myocardial Fibrosis in Post-heterotopic Heart Transplantation

  2017cites this paper
• Elevated Nuclear and Cytoplasmic FTY720-Phosphate in Mouse Embryonic Fibroblasts Suggests the Potential for Multiple Mechanisms in FTY720-Induced Neural Tube Defects.

  2016cites this paper
• Sphingosine-1-phosphate metabolism: A structural perspective

  2015cites this paper
• An Unusual Association of Demyelinating Disease, Chronic Kidney Disease and Heart Failure

  2015cites this paper
• Targeted delivery as key for the success of small osteoinductive molecules.

  2015cites this paper